<DOC>
	<DOC>NCT02379910</DOC>
	<brief_summary>This is a study of safety, tolerability, pharmacokinetics and pharmacodynamics of AM1030-CREAM in patients with Atopic Dermatitis.</brief_summary>
	<brief_title>A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Males and/or females of any ethnic origin between 18 and 65 years of age Body mass index between 18.0 and 35.0 kg/m2 Subjects with AD as defined by the Hanifen and Rajka criteria and with mild to severe disease activity (IGA 24) AD lesions amenable to cutaneous treatment located on the trunk and/or limbs Subjects with scars, moles, tattoos, sunburn or other blemishes in test areas Systemic treatment with immunosuppressants, immunomodulators or corticosteroids within 2 weeks prior to dosing Topical treatment with corticosteroids, antibiotics and/or immunomodulators within 4 days prior to dosing Treatment with systemic antihistamines within 24 hours of the first dose administration Treatment with SSRIs within 2 weeks of the first dose administration Subjects who have received phototherapy within 4 weeks prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>